Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy:: A post hoc analysis of RENAAL

被引:75
作者
de Zeeuw, D
Ramjit, D
Zhang, Z
Ribeiro, AB
Kurokawa, K
Lash, JP
Chan, J
Remuzzi, G
Brenner, BM
Shahinfar, S
机构
[1] Univ Groningen, Med Ctr, Dept Clin Pharmacol, NL-9713 AV Groningen, Netherlands
[2] Merck & Co Inc, Merck Res Labs, Whitehouse Stn, NJ USA
[3] UNIFESP, EPM, Div Nephrol, Hosp Rim Hipertensao,Fdn Oswaldo Ramos, Sao Paulo, Brazil
[4] Tokai Univ, Sch Med, Kanagawa 2591100, Japan
[5] Univ Illinois, Dept Med, Nephrol Sect, Chicago, IL USA
[6] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China
[7] Mario Negri Inst Pharmacol Res, I-24100 Bergamo, Italy
[8] Brigham & Womens Hosp, Div Renal, Boston, MA 02115 USA
[9] Harvard Univ, Sch Med, Boston, MA 02115 USA
关键词
albuminuria; proteinuria; ethnicity; type; 2; diabetes; losartan; ESRD;
D O I
10.1038/sj.ki.5000326
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Type 2 diabetes is becoming the leading cause of end-stage renal disease ( ESRD) worldwide. Prevalence of ESRD and the antihypertensive response to renin-angiotensin system intervention are suggested to vary among different ethnicities. The Reduction in Endpoints in Non-insulin dependent diabetes mellitus with the Angiotensin II Antagonist Losartan (RENAAL) study, which included different ethnic groups, demonstrated a renoprotective effect of losartan. A post hoc analysis from RENAAL was performed where we examined in each ethnic group the ESRD risk, identified independent predictors for ESRD, effect of degree of baseline albuminuria, effect of 6-month antiproteinuric response to therapy on ESRD, and renoprotective effect of losartan assessed by albuminuria reduction and ESRD. Baseline albuminuria was the strongest predictor for ESRD in every ethnic group. Albuminuria reduction was associated with reduced risk of ESRD while losartan reduced albuminuria in every ethnic group. When accounting for independent predictors of ESRD, losartan exhibited renoprotection in all ethnic groups. In this type 2 diabetic population with nephropathy, baseline albuminuria is the predominant risk parameter for ESRD; early antiproteinuric effect of losartan predicts long- term renoprotection; and losartan appears to be renoprotective in all ethnic groups. Since the RENAAL study was not powered to determine ethnic responses, these results underline the need for prospective trials where the aim is renal protection among different ethnic groups.
引用
收藏
页码:1675 / 1682
页数:8
相关论文
共 47 条
[1]   Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis - A randomized controlled trial [J].
Agodoa, LY ;
Appel, L ;
Bakris, GL ;
Beck, G ;
Bourgoignie, J ;
Briggs, JP ;
Charleston, J ;
Cheek, D ;
Cleveland, W ;
Douglas, JG ;
Douglas, M ;
Dowie, D ;
Faulkner, M ;
Gabriel, A ;
Gassman, J ;
Greene, T ;
Hall, Y ;
Hebert, L ;
Hiremath, L ;
Jamerson, K ;
Johnson, CJ ;
Kopple, J ;
Kusek, J ;
Lash, J ;
Lea, J ;
Lewis, JB ;
Lipkowitz, M ;
Massry, S ;
Middleton, J ;
Miller, ER ;
Norris, K ;
O'Connor, D ;
Ojo, A ;
Phillips, RA ;
Pogue, V ;
Rahman, M ;
Randall, OS ;
Rostand, S ;
Schulman, G ;
Smith, W ;
Thornley-Brown, D ;
Tisher, CC ;
Toto, RD ;
Wright, JT ;
Xu, SC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (21) :2719-2728
[2]  
American Diabetes Association, 2003, DIABETES CARE S1, V26, pS83
[3]  
AMOS AF, 1997, DIABETIC MED, V14, P7
[4]  
APPERLOO AJ, 1994, KIDNEY INT, V45, pS174
[5]   Effects of blood pressure level on progression of diabetic nephropathy - Results from the RENAAL study [J].
Bakris, GL ;
Weir, MR ;
Shanifar, S ;
Zhang, ZX ;
Douglas, J ;
van Dijk, DJ ;
Brenner, BM .
ARCHIVES OF INTERNAL MEDICINE, 2003, 163 (13) :1555-1565
[6]  
Brenner B M, 2000, J Renin Angiotensin Aldosterone Syst, V1, P328, DOI 10.3317/jraas.2000.062
[7]   Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy [J].
Brenner, BM ;
Cooper, ME ;
de Zeeuw, D ;
Keane, WF ;
Mitch, WE ;
Parving, HH ;
Remuzzi, G ;
Snapinn, SM ;
Zhang, ZX ;
Shahinfar, S .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :861-869
[8]   Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes - An Asian perspective from the RENAAL study [J].
Chan, JCN ;
Wat, NMS ;
So, WY ;
Lam, KSL ;
Chua, CT ;
Wong, KS ;
Morad, Z ;
Dickson, TZ ;
Hille, D ;
Zhang, ZX ;
Cooper, ME ;
Shahinfar, S ;
Brenner, BM ;
Kurokawa, K .
DIABETES CARE, 2004, 27 (04) :874-879
[9]   DISPARITIES IN INCIDENCE OF DIABETIC END-STAGE RENAL-DISEASE ACCORDING TO RACE AND TYPE OF DIABETES [J].
COWIE, CC ;
PORT, FK ;
WOLFE, RA ;
SAVAGE, PJ ;
MOLL, PP ;
HAWTHORNE, VM .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (16) :1074-1079
[10]   Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy [J].
de Zeeuw, D ;
Remuzzi, G ;
Parving, HH ;
Keane, WF ;
Zhang, ZX ;
Shahinfar, S ;
Snapinn, S ;
Cooper, ME ;
Mitch, WE ;
Brenner, BM .
CIRCULATION, 2004, 110 (08) :921-927